1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
  5. > CNS Drug News 04 JANUARY 2016

CNS Drug News 04 JANUARY 2016

  • January 2016
  • -
  • Espicom Business Intelligence
  • -
  • 12 pages

Industry Trend Analysis - Compliance Will Be Key In Future CNS Medication
Industry Trend Analysis - LID Success Will Allow Adamas To Grow
Industry Brief - Intec Receives IRB Approval To Initiate AP-COLD Phase III PD Trial
Industry Brief - ADS-5102 Phase III EASE LID Trial Meets Primary Endpoint
Industry Brief - Enrolment Begins In ND0612H Phase II Trial In Advanced PD
Industry Trend Analysis - Laquinimod Viability In Doubt
Industry Brief - GeNeuro Initiates GNbAC1 Phase IIb Trial In RRMS
Industry Trend Analysis - Fast Track Designation Supporting Mid-term Operations
Industry Brief - Aquinnah Secures USD5mn Investment From Takeda To Advance ALS Therapies
Industry Brief - Radicut Approved In South Korea For ALS
Industry Brief - Sanbio/Sunovion Begin Regenerative Therapy Phase IIb Trial For Chronic Stroke
Industry Brief - ICT Begins Enrolment For ITI-007 Phase III Trials In Bipolar Depression
Industry Brief - Pristiq Phase III Paediatric MDD Study Misses Primary Endpoint
Industry Brief - EMA Accepts Fanaptum MAA For Schizophrenia In Adults
Industry Brief - Egalet Submits Arymo NDA In US
Industry Brief - Antares Gains FDA Sumatriptan Approval
Industry Brief - FDA Approves Merck's Bridion For Reversal Of NMB
Industry Brief - Hikma Gains FDA Neostigmine Approval
Industry Brief - CHMP Accepts AcelRx' ARX-04 MAA For Centralised Review
Industry Brief - Depomed Acquires Certain Rights To Cebranopadol From Grunenthal
Industry Brief - First Patient Enrolled In Phase III Efficacy Trial Of CAM2038
Industry Brief - Neurelis Receives FDA ODD For NRL-1 In Acute Repetitive Seizures
Industry Brief - FDA Accepts Zogenix' IND For ZX003 Phase III Trial In Dravet Syndrome
Industry Brief - Interim Results From Alexza AZ-002 Phase IIa Study In ARS
Industry Trend Analysis - ULS Indication Will Not Revitalise Xeomin
Industry Brief - Ionis Earns Milestone In Neurology Collaboration With Biogen
Industry Brief - Cantabio/Gardedam Complete Merger

Table Of Contents

CNS Drug News 04 JANUARY 2016

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
Neurological Disorder Drugs Market - Europe Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Neurological Disorder Drugs Market - Europe Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • December 2016
  • by Transparency Market Research

Europe Neurological Disorder Drugs Market: Overview This report on the neurological disorder drugs market studies the current as well as future prospects of the market in Europe. Health concern related ...

Epiomic Epidemiology Series: Lewy Body Dementia Forecast in 12 Major Markets 2017-2027

Epiomic Epidemiology Series: Lewy Body Dementia Forecast in 12 Major Markets 2017-2027

  • $ 5112
  • Industry report
  • February 2017
  • by Black Swan Analysis Ltd

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Lewy Body Dementia in 12 Major Markets Dementia with Lewy Bodies (DLB) is the second most frequent cause of age related neurodegenerative ...

Epiomic Epidemiology Series: Alzheimer%s Disease Forecast in 12 Major Markets 2017-2027

Epiomic Epidemiology Series: Alzheimer%s Disease Forecast in 12 Major Markets 2017-2027

  • $ 5112
  • Industry report
  • February 2017
  • by Black Swan Analysis Ltd

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Alzheimer’s disease in 12 Major Markets Alzheimer's disease (AD) is a progressive, irreversible neurodegenerative disorder. It is ...


ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.